Business / Finance

RSS

Cord Blood America’s 2015 second quarter revenue increases 39.0% to $1.41 million

Cord Blood America, Inc. today announced financial results for the second quarter ended June 30, 2015.

14 Aug 2015

CASI reports financial results for second quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and six months ended June 30, 2015.

14 Aug 2015

China Pharma Holdings revenue decreases 7.4% to $5.7 million in Q2 2015

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended June 30, 2015.

14 Aug 2015

WuXi PharmaTech signs definitive and merger agreements

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of Parent.

14 Aug 2015

Nutrastar's net revenue increases 1.8% to $13.24 million in second quarter 2015

Nutrastar International Inc., a leading producer and supplier of premium branded consumer products, including commercially cultivated Cordyceps Militaris ("Cordyceps"), functional health beverages and organic and specialty foods, today announced its results for the three months and six months ended June 30, 2015.

13 Aug 2015

Rhythm Metabolic completes $40 million Series A financing

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.

13 Aug 2015

Dipexium reports net loss of $4.0 million for second quarter 2015

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015.

13 Aug 2015

CrystalGenomics signs agreement with Dong-A ST for commercialization of Acelex (polmacoxib) in Korea

CrystalGenomics, Inc. has announced that it has signed a Sales and Marketing Agreement with Dong-A ST Co., Ltd. for the commercialization of Acelex (polmacoxib) in Korea.

13 Aug 2015

Lucideon acquires second Dynamic Secondary Ion Mass Spectrometer

Lucideon is pleased to announce the acquisition of a second Dynamic Secondary Ion Mass Spectrometer (DSIMS). The investment doubles the capacity for DSIMS analysis at Lucideon and represents a response to the demand for the service and Lucideon’s commitment to satisfying customer requirements.

From Lucideon 12 Aug 2015

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.

12 Aug 2015

Concord Medical closes acquisition of additional ownership interest in MD Anderson Proton Therapy Center

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has closed the acquisition of additional ownership interest of The University of Texas MD Anderson Cancer Center Proton Therapy Center ("MD Anderson Proton Therapy Center").

12 Aug 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.

12 Aug 2015

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Janssen Biotech, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies.

12 Aug 2015

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC.

11 Aug 2015

Endra photoacoustic CT preclinical imaging technology to be brought to Australia by AXT

AXT is proud to announce that they have just signed an exclusive distributorship agreement with US-based Endra Life Sciences. Endra are a developer of photoacoustic (PA) technology for bio-medical imaging and have commercialised their breakthrough technology. This new deal further bolsters AXT’s life science and preclinical imaging portfolios with another unique technology.

From MR Solutions 11 Aug 2015

VolitionRx reports net loss of $1.9 million for second quarter 2015

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the second quarter ended June 30, 2015.

11 Aug 2015

Deerfield provides $20 million financing to Editas Medicine

Deerfield Management Company, L.P.'s venture capital fund, Deerfield Healthcare Innovations Fund, L.P., today announced its first therapeutics-based investment by participating, along with Deerfield Private Design Fund III, in providing financing to Editas Medicine. In total, Deerfield invested $20 million in this early-stage institutional financing.

10 Aug 2015

BioScrip revenue increases 6.2% to $262.4 million in second quarter 2015

BioScrip, Inc. today announced 2015 second quarter financial results. Second quarter revenue from continuing operations was $262.4 million and the net loss from continuing operations was $243.2 million, or $3.60 loss per diluted share, which includes a $238.0 million pre-tax goodwill impairment charge resulting from a decline in the Company's common stock price and related market capitalization, as well as an $8.6 million incremental pre-tax bad debt charge predominately attributable to aged accounts receivable balances over 365 days old.

10 Aug 2015

Impax sells U.S. rights to Daraprim brand for $55 million to Turing Pharmaceuticals

Impax Laboratories, Inc. today announced that it has sold its U.S. rights to the Daraprim brand to Turing Pharmaceuticals AG for approximately $55 million.

10 Aug 2015

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

10 Aug 2015

Business / Finance

Cord Blood America’s 2015 second quarter revenue increases 39.0% to $1.41 million

CASI reports financial results for second quarter 2015

China Pharma Holdings revenue decreases 7.4% to $5.7 million in Q2 2015

WuXi PharmaTech signs definitive and merger agreements

Nutrastar's net revenue increases 1.8% to $13.24 million in second quarter 2015

Rhythm Metabolic completes $40 million Series A financing

Dipexium reports net loss of $4.0 million for second quarter 2015

CrystalGenomics signs agreement with Dong-A ST for commercialization of Acelex (polmacoxib) in Korea

Lucideon acquires second Dynamic Secondary Ion Mass Spectrometer

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Concord Medical closes acquisition of additional ownership interest in MD Anderson Proton Therapy Center

Ardelyx reports net income of $9.0 million for second quarter 2015

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Endra photoacoustic CT preclinical imaging technology to be brought to Australia by AXT

VolitionRx reports net loss of $1.9 million for second quarter 2015

Deerfield provides $20 million financing to Editas Medicine

BioScrip revenue increases 6.2% to $262.4 million in second quarter 2015

Impax sells U.S. rights to Daraprim brand for $55 million to Turing Pharmaceuticals

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Latest News